GSK’s malaria vaccine closer to use in Africa




Whatsapp News

By Lexi Elo

The world’s first , made by GlaxoSmithKline, could be approved by international regulators for use in Africa October after final trial data showed it offered partial protection for up to four years.

The , RTS,S,  is designed for children in Africa and would be the first licensed human against a parasitic disease and could help prevent millions of cases of , which currently kills more than 600,000 annually.

have long hoped scientists would be able to develop an effective , and researchers at the British drugmaker GSK have been working on RTS,S for 30 years.

Hopes that this shot would be the final answer to wiping out malaria were dampened when trial data released in 2011 and 2012 showed it only reduced episodes of malaria in babies aged 6-12 weeks by 27 percent, and by around 46 percent in children aged 5-17 months.

However, final stage follow-up data published in the Lancet journal on Friday showed vaccinated children continued to be protected four years on, albeit at a declining rate — an important factor given the prevalence of the disease — and rates of protection were stronger a booster shot.

[pro_ad_display_adzone id=”10″]

“Despite the falling efficacy time, there is still a clear benefit RTS,S,” said Brian Greenwood, a professor at the London School of Hygiene & Tropical Medicine who worked on the study.

He said an average 1,363 cases of clinical malaria were prevented four years for every 1,000 children vaccinated, or 1,774 cases a booster shot — the children would normally be expected to have had several cases of infection that period.

In babies, over three years of follow-up, an average 558 cases were prevented for every 1,000 vaccinated, and 983 cases in those who got a booster.

“Given that there were an estimated 198 million malaria cases in 2013, this level of efficacy potentially translates into millions of cases of malaria in children being prevented,” Greenwood said.

GSK submitted an application in July 2014 for regulatory approval by the European Medicines Agency for RTS,S and is expecting a decision within a few months. If it a license, the World Health Organization could recommend it for use “as early as October this year”, Greenwood said.

say RTS,S be only among several against malaria, alongside insecticide-treated bednets, rapid diagnostic tests and anti-malarial drugs.

RTS,S co-developed by GSK and the non-profit PATH Malaria Vaccine Initiative, funding the & Melinda Gates Foundation.